← FDA DRUG APPROVALS

FDA NDA · NDA008693

FURADANTIN

Sponsor: PROCTER AND GAMBLE

APPLICATION
NDA008693
TYPE
NDA
ORIGINAL APPROVAL
1953-02-06
LATEST ACTION
1998-02-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

FURADANTINDiscontinued
NITROFURANTOIN 100MG · TABLET · ORAL
FURADANTINDiscontinued
NITROFURANTOIN 50MG · TABLET · ORAL

Approval history

1998-02-17Labeling · Supplement 28 · priorityAP
1998-02-17Labeling · Supplement 26 · priorityAP
1997-07-16Labeling · Supplement 30 · priorityAP
1997-03-27Labeling · Supplement 29 · priorityAP
1993-08-09Manufacturing (CMC) · Supplement 27 · priorityAP
1993-05-18Efficacy · Supplement 20 · priorityAP
1988-05-13Labeling · Supplement 25 · priorityReviewAP
1983-07-14Manufacturing (CMC) · Supplement 21 · priorityAP
1982-11-18Labeling · Supplement 19 · priorityAP
1979-12-17Labeling · Supplement 16 · priorityAP
1979-06-29Manufacturing (CMC) · Supplement 17 · priorityAP
1979-03-16Manufacturing (CMC) · Supplement 15 · priorityAP
1976-06-30Manufacturing (CMC) · Supplement 10 · priorityAP
1976-05-11Manufacturing (CMC) · Supplement 11 · priorityAP
1953-02-06Type 1 - New Molecular Entity · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →